Abstract:ABSTRACT Both human and non-human simian adenoviruses (HAdVs and SAdVs, respectively) have been used as gene therapy and vaccine vectors. The high prevalence of HAdVs and the neutralizing antibodies associated with prior infection, may limit HAdV-based vector use in human subjects. To overcome this drawback, a vector derived from a newly isolated and characterized macaque adenovirus was constructed. SAdVs (33.9%) were screened from 115 SAdV fecal samples collected at a zoological park. One novel SAdV was isolated and the whole genome was sequenced and analyzed. The pre-existing neutralizing antibody levels were very low against this isolate (10%). Interestingly, SAdV vector constructs that lack E3 region could not produce infectious progeny in HEK293 cells, suggesting that the E3 region is necessary for SAdV replication. The absence of E3 region could be compensated for by replacement with HAdV-5 E4orf6; the resultant construct could replicate well in HEK293 cells. The enhanced Green Fluorescent Protein (eGFP) was inserted into SAdV E3 region and expressed at high level. One-step growth curve showed that the replication of the SAdVs with HAdV-5 E4orf6 substitution and E1/E3 deletion was similar to that of wild-type SAdVs in HEK293 cells, but the modified SAdVs were replication-deficient in A549 cells which lack HAdV-5 E1A and E1B. Finally, we demonstrated that GZ3-12 could infect cells expressing hCAR or hDSG2 receptors. The successful isolation, characterization, and modification of novel SAdVs provide a potentially important vaccine and gene therapy candidate and a new strategy for the rapid acquisition and development of non-HAdV-based alternative vectors for human health applications. Adenoviruses are widely used in gene therapy and vaccine delivery. Due to the high prevalence of human adenoviruses (HAdVs), the pre-existing immunity against HAdVs in humans is common, which limits the wide and repetitive use of HAdV vectors. In contrast, the pre-existing immunity against simian adenoviruses (SAdVs) is low in humans. Therefore, we performed epidemiological investigations of SAdVs in simians and found that the SAdV prevalence was as high as 33.9%. The whole-genome sequencing and sequence analysis showed SAdV diversity and possible cross species transmission. One isolate with low level of pre-existing neutralizing antibodies in humans was used to construct replication-deficient SAdV vectors with E4orf6 substitution and E1/E3 deletion. Interestingly, we found that the E3 region plays a critical role in its replication in human cells, but the absence of this region could be compensated for by the E4orf6 from HAdV-5 and the E1 expression intrinsic to HEK293 cells.

Chimpanzee Adenovirus Antibodies in Humans, Sub-Saharan Africa

The Genome Sequence of A Novel Simian Adenovirus in A Chimpanzee Reveals A Close Relationship to Human Adenoviruses

Multiple Cross-Species Transmission Events of Human Adenoviruses (HAdV) during Hominine Evolution

Isolation and characterization of adenoviruses infecting endangered golden snub-nosed monkeys (Rhinopithecus roxellana)

Infectivity of human group B adenovirus to cells from different species

Both haemagglutinin-specific antibody and T cell responses induced by a chimpanzee adenoviral vaccine confer protection against influenza H7N9 viral challenge

Novel Simian Foamy Virus Infections from Multiple Monkey Species in Women from the Democratic Republic of Congo

Neutralizing Antibody Responses to Enterovirus and Adenovirus in Healthy Adults in China

Antibody Responses of Chimpanzees Immunized with Synthetic Peptides Corresponding to Full-Length V3 Hypervariable Loops of HIV-1 Envelope Glycoproteins.

Adenovirus-specific T cells in adults are frequent, cross-reactive to common childhood adenovirus infections and boosted by adenovirus-vectored vaccines

Seroprevalence of Neutralizing Antibodies Against Adenovirus Type 14 and 55 in Healthy Adults in Southern China

Seroprevalence of neutralizing antibodies against adenovirus type 14 and 55 in healthy adults in Southern China <subtitle>Prevalence of Ad14 and 55-neutralizing antibodies</subtitle>

Viral Metagenomics of Fecal Samples from Non-Human Primates Revealed Human Astrovirus in a Chimpanzee, China

Seroprevalence of Neutralizing Antibodies to Human Adenovirus Type 4 and 7 in Healthy Populations from Southern China

Adaptation of CD4 in gorillas and chimpanzees conveyed resistance to simian immunodeficiency viruses

[Monocytes Are More Susceptible in Vitro in Rhesus Macaques of Chinese Origin to Recombinant Serotype 5 Adenovirus with Higher Preexisting Vector Specific Neutralizing Antibody Titer].

Potentially Zoonotic Enteric Infections in Gorillas and Chimpanzees, Cameroon and Tanzania

Single Intranasal Immunization with Chimpanzee Adenovirus-Based Vaccine Induces Sustained and Protective Immunity Against MERS-CoV Infection.

Epidemiology of Adenovirus Type 5 Neutralizing Antibodies in Healthy People and AIDS Patients in Guangzhou, Southern China.

Isolation of novel simian adenoviruses from macaques for development of a vector for human gene therapy and vaccines

Neutralizing monoclonal antibodies protect against human adenovirus type 55 infection in transgenic mice and tree shrews